Manubhai Amrutlal Shah has sold 8,00,000 shares, or 5.57%, of Bacil Pharma Ltd. in an open market transaction. This reduces his stake to 12.77%, impacting shareholding patterns.

Bacil Pharma Shareholding Change

Manubhai Amrutlal Shah has divested 8,00,000 equity shares, representing 5.57% of the total share capital, in Bacil Pharma Ltd. on June 10, 2026. This transaction was conducted through the open market route.

Reader Takeaway: Shareholder divestment adds supply; ownership shifts.

What just happened

Manubhai Amrutlal Shah's shareholding in Bacil Pharma Ltd. has decreased from 18.34% (26,31,709 shares) to 12.77% (18,31,709 shares). This reduction of 8,00,000 shares was executed via the open market on June 10, 2026, triggering disclosure requirements under SEBI regulations.

Why this matters

This sale by a significant shareholder increases the supply of shares in the secondary market. Investors should note the change in the company's ownership structure and monitor subsequent shareholding pattern disclosures for any further shifts among major stakeholders.

The backstory

Prior to this transaction, Manubhai Amrutlal Shah held a substantial 18.34% stake in Bacil Pharma Ltd. The company's total equity share capital comprises 1,43,53,000 equity shares of Rs. 10 each.

What changes now

Manubhai Amrutlal Shah's direct shareholding in Bacil Pharma is now 12.77%. The company's total equity share capital remains unchanged. The divestment is a direct result of the open market sale.

Risks to watch

Investors should observe if the increased supply from this divestment affects the stock price. Continued selling pressure or further disclosures of stake reduction by other large shareholders could pose a risk. The reasons behind the divestment are not stated, which may be a point of concern for some.

Context metrics (time-bound)

• Transaction Date: June 10, 2026
• Shares Disposed: 8,00,000 (5.57% of total equity)
• Previous Holding: 26,31,709 shares (18.34%)
• Current Holding: 18,31,709 shares (12.77%)

What to track next

Investors should closely monitor Bacil Pharma's future shareholding pattern disclosures to understand the broader impact of this sale and identify any potential new significant stakeholders or further changes in ownership.